Viridian Therapeutics receives FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease

Viridian Therapeutics, Inc.\DE

Lumvoa is the first FDA-approved treatment for TED with labeling covering both active and chronic disease.
Approval supported by positive Phase 3 THRIVE and THRIVE-2 trials meeting primary and all secondary endpoints.
Lumvoa showed statistically significant improvement in diplopia response and complete resolution in active and chronic TED.
Viridian plans to launch Lumvoa immediately with a comprehensive patient support program (ViridianCares).
Company will host a conference call on June 29, 2026, at 8:00 a.m. ET to discuss the approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.